AbbVie (ABBV) Capital Expenditures Growth (3y) (2015 - 2026)
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Capex Growth (3y) (Qtr) |
| 1 |
Novartis Ag |
107,124,802.25 Bn |
107,124,802.25 Bn |
- |
-27.23% |
| 2 |
Eli Lilly |
969.00 Bn |
963.72 Bn |
16.22 Bn |
51.53% |
| 3 |
Johnson & Johnson |
539.46 Bn |
517.41 Bn |
15.96 Bn |
6.72% |
| 4 |
AbbVie |
376.92 Bn |
367.57 Bn |
10.78 Bn |
14.83% |
| 5 |
Merck |
285.00 Bn |
279.35 Bn |
12.09 Bn |
-0.53% |
| 6 |
Amgen |
177.58 Bn |
165.55 Bn |
5.87 Bn |
27.44% |
| 7 |
Gilead Sciences |
163.22 Bn |
155.50 Bn |
5.52 Bn |
2.39% |
| 8 |
Pfizer |
145.86 Bn |
133.09 Bn |
-1.21 Bn |
-27.39% |
| 9 |
Bristol Myers Squibb |
111.90 Bn |
101.44 Bn |
8.07 Bn |
7.67% |
| 10 |
Gsk |
88.34 Bn |
83.66 Bn |
- |
- |
| Date | Value |
| Mar 31, 2026 |
14.83% |
| Dec 31, 2025 |
15.59% |
| Sep 30, 2025 |
29.12% |
| Jun 30, 2025 |
23.44% |
| Mar 31, 2025 |
13.20% |
| Dec 31, 2024 |
15.88% |
| Sep 30, 2024 |
4.69% |
| Jun 30, 2024 |
7.32% |
| Mar 31, 2024 |
0.88% |
| Dec 31, 2023 |
-9.76% |
| Sep 30, 2023 |
0.31% |
| Jun 30, 2023 |
0.19% |
| Mar 31, 2023 |
11.87% |
| Dec 31, 2022 |
9.33% |
| Sep 30, 2022 |
4.75% |
| Jun 30, 2022 |
3.76% |
| Mar 31, 2022 |
14.83% |
| Dec 31, 2021 |
14.99% |
| Sep 30, 2021 |
-8.36% |
| Jun 30, 2021 |
19.59% |
| Mar 31, 2021 |
16.47% |
| Dec 31, 2020 |
15.30% |
| Sep 30, 2020 |
19.87% |
| Jun 30, 2020 |
12.00% |
| Mar 31, 2020 |
9.58% |
| Dec 31, 2019 |
12.66% |
| Sep 30, 2019 |
10.87% |
| Jun 30, 2019 |
-0.77% |
| Mar 31, 2019 |
-4.02% |
| Dec 31, 2018 |
-5.34% |
| Sep 30, 2018 |
30.46% |
| Jun 30, 2018 |
-0.29% |
| Mar 31, 2018 |
-6.37% |
| Dec 31, 2017 |
5.96% |
| Sep 30, 2017 |
-11.21% |
| Jun 30, 2017 |
-3.91% |
| Mar 31, 2017 |
-11.49% |
| Dec 31, 2016 |
-8.94% |
| Sep 30, 2016 |
-5.29% |
| Jun 30, 2016 |
3.25% |
| Mar 31, 2016 |
11.20% |
| Dec 31, 2015 |
15.14% |
| Sep 30, 2015 |
108.44% |
| Jun 30, 2015 |
6.95% |
| Mar 31, 2015 |
-3.63% |